Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.

ABSTRACT:

Background

Novel targeted agents have been increasingly developed and tested in clinical trials over the past 5-10 years, many with unknown and unanticipated side effects. We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib-associated photoallergic dermatitis while enrolled on a phase 1 clinical trial.

Case presentation

A 51-year-old Caucasian female with poorly differentiated, metastatic follicular thyroid carcinoma presented with a cutaneous eruption that developed over 3 to 4 days while treated on phase 1 clinical trial with vandetanib-based therapy. Given the concern for photoallergic dermatitis, vandetanib was discontinued and supportive care provided including topical and oral steroid admin

SUBMITTER: Goldstein J 

PROVIDER: S-EPMC4336708 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature